小结
定义
病史和体格检查
关键诊断因素
- history of intensive chemotherapy regimens
- history of radiation therapy to the oral cavity
- history of chemoradiation
- erythema and/or ulceration of oral mucosa
- oral pain
其他诊断因素
- intraoral bleeding
- dietary impairment and/or weight loss
- diarrhea
- nausea and/or vomiting
- abdominal pain
- fever
危险因素
- intensive chemotherapy regimens
- radiation therapy to the oral cavity
- chemoradiation
- genetic polymorphisms in drug metabolic enzymes
- use of targeted therapies and immunotherapies
诊断性检查
首要检查
- clinical diagnosis
需考虑的检查
- CBC with differential
- blood cultures
- superficial smear of lesion for microscopy
- fungal culture
- viral culture or polymerase chain reaction (PCR)
治疗流程
undergoing hematopoietic stem cell transplant: preventive measures
receiving bolus fluorouracil: preventive measures
receiving radiation therapy to oral cavity: preventive measures
established oral mucositis
撰稿人
作者
Ourania Nicolatou-Galitis, DDS, MSc, DrDent
Dentist
Specialist in Oral Medicine and Oral Oncology
Hospital Dentistry
National & Kapodistrian University of Athens
Athens
Greece
利益声明
ONG has received fees from Angelini pharma to author a review article on oral mucositis and is the cofounder and scientific responsible of mycancer, a startup private company which aims to provide a comprehensive medical platform for cancer patients. ONG is an author of several references cited in this topic.
Nikolaos Tsoukalas, MD, MSc, PhD
Medical Oncologist
Associate Director
Department of Oncology
401 General Military Hospital
Athens
Greece
利益声明
NT declares that he has no competing interests.
鸣谢
Professor Ourania Nicolatou-Galitis and Dr Nikolaos Tsoukalas would like to gratefully acknowledge Dr Eleni Arvanitou, who contributed to the updating of this topic, and Dr Rajesh V. Lalla, a previous contributor.
利益声明
EA declares that she has no competing interests. RVL serves as a consultant for Galera Therapeutics, Ingalfarma, Mundipharma and Sucampo Pharma, and has received research funding from Onxeo, Sucampo Pharma, Galera Therapeutics, and Novartis.
同行评议者
Michael Brennan, DDS, MHS
Associate Chairman and Oral Medicine Residency Director
Department of Oral Medicine
Carolinas Medical Center
Charlotte
NC
利益声明
MB is an author of a reference cited in this topic. MB is part of the Mucositis Study Group of MASCC/ISOO, and participated in the review of mucositis.
Maria Michelagnoli, MB ChB, MD, FRCPCH
Consultant Pediatric and Adolescent Oncologist
University College London Hospitals
London
UK
利益声明
MM declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
参考文献
关键文献
Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1;126(19):4423-31.全文 摘要
Peterson DE, Boers-Doets CB, Bensadoun RJ, et al; ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v139-51.全文 摘要
参考文献
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
鉴别诊断
- Oral candidiasis
- Herpes simplex virus infection
- Graft-versus-host disease
更多 鉴别诊断指南
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
- Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines
更多 指南
登录或订阅即可浏览 BMJ Best Practice 临床实践完整内容
内容使用需遵循免责声明